GPBAR1 and steatosis: Finally, INT-767, a dual FXR and transmembrane G-protein-coupled receptor 5 (TGR5) agonist, dose dependently reduce cholesterol and liver triglyceride levels, reduce steatosis, inflammation, and fibrosis stage [29, 32].